B2M and plasma cell myeloma: Additionally, B2M monoclonal antibodies have been shown to exhibit therapeutic efficacy and low toxicity in human‐like myeloma mouse models, which express mature and functional human B2M in murine organs and present high levels of circulating human B2M derived from human myeloma cells.43